Search - tctmd.com

Displaying 221 - 240 of 266

Sort: Relevancy | Date

News Conference News ACC 2013

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

L.A. McKeown

March 14, 2013

News Conference News ACC 2013

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

Yael L. Maxwell

March 11, 2013

News Conference News ACC 2013

PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device

L.A. McKeown

March 09, 2013

News Daily News

STS Meeting Looks at New TAVR Device and Reviews Valve Procedure Rates in the UK

Jason Kahn

January 28, 2013

News Daily News

European Registry: TAVR Devices Show Similar Short-, Long-term Outcomes

Caitlin E. Cox

January 16, 2013

News Industry News

First Results from Medtronic Engager™ European Pivotal Trial Demonstrate Positive Outcomes

October 29, 2012

News Conference News TCT 2012

Registries Show TAVR Evolution in UK, Internationally

October 24, 2012

Presentation TCT 2012

Endoluminal Sciences: A New Concept for Eliminating Paravalvular Regurgitation

Presenter: Raj Makkar

October 24, 2012

News Industry News

Neovasc's Tiara™ transcatheter mitral valve selected as a best new device concept at TCT 2012 Scientific Symposium

October 23, 2012

News Industry News

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

October 23, 2012

Presentation TCT 2012

Reduces Paravalvular Regurgitation

Presenter: Benoit Daneault

October 22, 2012

Presentation TCT 2012

Paravalvular Regurgitation as a Strong Predictor of Post-TAVR Mortality

Presenter: Susheel Kodali

October 22, 2012

Presentation TCT 2012

3-D Annulus Sizing (using MSCT or 3-D Echo) Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Presenter: Hasan Jilaihawi

October 22, 2012

News Industry News

First Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System

October 10, 2012

News Conference News ESC 2012

Dedicated Transapical TAVR Device Shows Promise in Premarket Clinical Research

Caitlin E. Cox

August 28, 2012

News Conference News ESC 2012

Predictors of Aortic Regurgitation After TAVR Delineated

August 26, 2012

News Daily News

JAMA Viewpoint: TAVR Promise Must Be Weighed Against Risks, Limitations

Yael L. Maxwell

August 09, 2012

News Daily News

TAVR Achieves Positive Short-term Outcomes in Bicuspid Valves

Jason Kahn

June 18, 2012

News Industry News

Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer

June 13, 2012

Presentation TVT 2012

Undersized TAVR with Paravalvular Regurgitation

Presenter: 204207|Georg Nickenig

June 02, 2012

Advertisement

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

PARTNER: TAVR Still Safe, Effective at 3 Years, Stroke Risk Diminished

PARTNER II Cohort B Demonstrates Safety, Efficacy of Lower Profile TAVR Device

STS Meeting Looks at New TAVR Device and Reviews Valve Procedure Rates in the UK

European Registry: TAVR Devices Show Similar Short-, Long-term Outcomes

First Results from Medtronic Engager™ European Pivotal Trial Demonstrate Positive Outcomes

Registries Show TAVR Evolution in UK, Internationally

Endoluminal Sciences: A New Concept for Eliminating Paravalvular Regurgitation

Neovasc's Tiara™ transcatheter mitral valve selected as a best new device concept at TCT 2012 Scientific Symposium

Boston Scientific Demonstrates Ongoing Structural Heart Advances at Transcatheter Cardiovascular Therapeutics 2012 in Miami

Reduces Paravalvular Regurgitation

Paravalvular Regurgitation as a Strong Predictor of Post-TAVR Mortality

3-D Annulus Sizing (using MSCT or 3-D Echo) Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

First Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System

Dedicated Transapical TAVR Device Shows Promise in Premarket Clinical Research

Predictors of Aortic Regurgitation After TAVR Delineated

JAMA Viewpoint: TAVR Promise Must Be Weighed Against Risks, Limitations

TAVR Achieves Positive Short-term Outcomes in Bicuspid Valves

Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer

Undersized TAVR with Paravalvular Regurgitation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content